Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Carcinoma × Etoposide × Clear all

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 3 Multiple Myeloma 2 Hematologic Neoplasms 2 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Fallopian Tube Neoplasms 1 Carcinoma 1

Interventions

Sorafenib 1 Etoposide 1 Cisplatin 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05910177 2024-03-06

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Fujian Cancer Hospital

Phase 2 Recruiting

Carcinoma, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡